Page 56 - Read Online

Spieler et al. Hepatoma Res 2019;5:4 I http://dx.doi.org/10.20517/2394-5079.2018.77 Page 13 of 13

Oncol 2015;5:e443-9.
53. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
54. Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, et al. Therapeutic potential of lenvatinib for unresectable
hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 2018; doi: 10.1111/hepr.13243.
55. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother
Cancer 2016;4:51.
56. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
57. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
58. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. Available from:
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625705.htm. [Last accessed on 7 Jan 2019]
59. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
60. Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM, et al. Building immunity to cancer with radiation therapy.
Cancer Lett 2015;368:198-208.
61. Chen L, Narang A, Thompson E, Anders R, Waters K, et al. Characterizing tumor infiltrating lymphocytes following neoadjuvant
chemotherapy and radiation in pancreatic adenocarcinoma. Int J Radiat Biol Phys 2017;99:S91-2.
62. Reese AS, Feigenberg SJ, Husain A, Webb TJ, Hausner PF, et al. Stereotactic ablative radiotherapy (SABR): impact on the immune
system and potential for future therapeutic modulation. Mol Cell Pharmacol 2013;5:19-25.
63. Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, et al. Radiation improves antitumor effect of immune checkpoint inhibitor in murine
hepatocellular carcinoma model. Oncotarget 2017;8:41242-55.
64. Gustafson MP, Bornschlegl S, Park SS, Gastineau DA, Roberts LR, et al. Comprehensive assessment of circulating immune cell
populations in response to stereotactic body radiation therapy in patients with liver cancer. Adv Radiat Oncol 2017;2:540-7.
65. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, et al. A phase I trial of stereotactic body radiation therapy
(SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-8.
66. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys
2010;76:S94-100.
67. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, et al. Stereotactic body radiation therapy: the report of AAPM task
group 101. Med Phys 2010;37:4078-101.
68. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, et al. Phase I feasibility trial of stereotactic body radiation therapy for
primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-25.
69. El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, et al. In intermediate stage hepatocellular carcinoma: radioembolization with
yttrium 90 or chemoembolization? Liver Int 2015;35:627-35.
70. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, et al. Radioembolization for hepatocellular carcinoma using yttrium-90
microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.